Takeda Pharmaceutical (TAK) Amortization - Intangibles (2019 - 2026)

Takeda Pharmaceutical has reported Amortization - Intangibles for 7 years, with the latest figure at -$824.5 million in Q1 2026.

• On a quarterly basis, Amortization - Intangibles rose 9.24% year-over-year to -$824.5 million in Q1 2026; TTM through Mar 2026 was -$5.5 billion, a 0.12% change from a year earlier, with the FY2026 full-year figure at -$824.5 million, up 9.39% from the prior year.
• Amortization - Intangibles was -$824.5 million for Q1 2026 at Takeda Pharmaceutical, up from -$887.0 million in the prior quarter.
• The five-year high for Amortization - Intangibles was -$810.5 million in Q4 2022, with the low at -$2.8 billion in Q3 2025.
• Average Amortization - Intangibles over 5 years is -$1.4 billion, with a median of -$933.3 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Amortization - Intangibles fell 11.69% in 2023, then advanced 9.24% in 2026.
• Over 5 years, Amortization - Intangibles stood at -$810.5 million in 2022, then dropped by 11.69% to -$905.2 million in 2023, then rose by 0.81% to -$897.9 million in 2024, then climbed by 1.21% to -$887.0 million in 2025, then rose by 7.04% to -$824.5 million in 2026.
• The last three Amortization - Intangibles figures came in at -$824.5 million (Q1 2026), -$887.0 million (Q4 2025), and -$2.8 billion (Q3 2025), per Business Quant data.